Literature DB >> 21342450

Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques.

A P Turner1, V O Shaffer, K Araki, C Martens, P L Turner, S Gangappa, M L Ford, R Ahmed, A D Kirk, C P Larsen.   

Abstract

Sirolimus is a potent antiproliferative agent used clinically to prevent renal allograft rejection. However, little is known about the effects of maintenance immunosuppressive agents on the immune response to potentially protective vaccines. Here we show that sirolimus paradoxically increases the magnitude and quality of the CD8+ T-cell response to vaccinia vaccination in nonhuman primates, fostering more robust recall responses compared to untreated and tacrolimus-treated controls. Enhancement of both the central and effector memory compartments of the vaccinia-specific CD8+ T-cell response was observed. These data elucidate new mechanistic characteristics of sirolimus and suggest immune applications extending beyond its role as an immunosuppressant. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342450      PMCID: PMC3076606          DOI: 10.1111/j.1600-6143.2010.03407.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  19 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Antibody to a lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-deficient mice.

Authors:  Shivaprakash Gangappa; Sharookh B Kapadia; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 3.  Immunosuppressive drugs for kidney transplantation.

Authors:  Philip F Halloran
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

Review 4.  Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.

Authors:  Lukena U Karkhanis; Ted M Ross
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

5.  Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.

Authors:  David San Segundo; Juan Carlos Ruiz; María Izquierdo; Gema Fernández-Fresnedo; Carlos Gómez-Alamillo; Ramón Merino; María Jesús Benito; Eva Cacho; Emilio Rodrigo; Rosa Palomar; Marcos López-Hoyos; Manuel Arias
Journal:  Transplantation       Date:  2006-08-27       Impact factor: 4.939

Review 6.  Use of sirolimus in solid organ transplantation.

Authors:  Joshua J Augustine; Kenneth A Bodziak; Donald E Hricik
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses.

Authors:  Ivana R Ferrer; Maylene E Wagener; Jennifer M Robertson; Alexa P Turner; Koichi Araki; Rafi Ahmed; Allan D Kirk; Christian P Larsen; Mandy L Ford
Journal:  J Immunol       Date:  2010-07-14       Impact factor: 5.422

8.  Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells.

Authors:  Holger Hackstein; Timucin Taner; Alison J Logar; Angus W Thomson
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

9.  Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.

Authors:  Francisco M Marty; Julie Bryar; Sarah K Browne; Talya Schwarzberg; Vincent T Ho; Ingrid V Bassett; John Koreth; Edwin P Alyea; Robert J Soiffer; Corey S Cutler; Joseph H Antin; Lindsey R Baden
Journal:  Blood       Date:  2007-03-28       Impact factor: 22.113

10.  Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.

Authors:  Abdolreza Haririan; Katherina Morawski; Miguel S West; Jose M El-Amm; Mona D Doshi; Elizabeth Cincotta; George J Alangaden; Pranatharthi Chandrasekar; Scott A Gruber
Journal:  Clin Transplant       Date:  2007 Jul-Aug       Impact factor: 2.863

View more
  53 in total

Review 1.  Metabolic regulation of T cell differentiation and function.

Authors:  Benjamin V Park; Fan Pan
Journal:  Mol Immunol       Date:  2015-08-12       Impact factor: 4.407

Review 2.  mTOR and metabolic regulation of conventional and regulatory T cells.

Authors:  Chaohong Liu; Nicole M Chapman; Peer W F Karmaus; Hu Zeng; Hongbo Chi
Journal:  J Leukoc Biol       Date:  2015-02-24       Impact factor: 4.962

3.  mTOR inhibitors for treatment of low-risk prostate cancer.

Authors:  Michael A Liss; Lanette Rickborn; John DiGiovanni; Dean Bacich; Linda A DeGraffenried; Manish Parihar; Ian M Thompson; Zelton Dave Sharp
Journal:  Med Hypotheses       Date:  2018-06-05       Impact factor: 1.538

4.  Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.

Authors:  Yohei Mineharu; Neha Kamran; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Cancer Ther       Date:  2014-09-25       Impact factor: 6.261

Review 5.  Post-transplantation malignancies: here today, gone tomorrow?

Authors:  Edward K Geissler
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 6.  Paradoxical aspects of rapamycin immunobiology in transplantation.

Authors:  I R Ferrer; K Araki; M L Ford
Journal:  Am J Transplant       Date:  2011-04       Impact factor: 8.086

Review 7.  T-cell metabolism governing activation, proliferation and differentiation; a modular view.

Authors:  Sarah Dimeloe; Anne-Valérie Burgener; Jasmin Grählert; Christoph Hess
Journal:  Immunology       Date:  2016-08-23       Impact factor: 7.397

8.  Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.

Authors:  H Xu; K P Samy; A Guasch; S I Mead; A Ghali; A Mehta; L Stempora; A D Kirk
Journal:  Am J Transplant       Date:  2015-10-05       Impact factor: 8.086

Review 9.  Integrating canonical and metabolic signalling programmes in the regulation of T cell responses.

Authors:  Kristen N Pollizzi; Jonathan D Powell
Journal:  Nat Rev Immunol       Date:  2014-07       Impact factor: 53.106

10.  IL-12hi rapamycin-conditioned dendritic cells mediate IFN-γ-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease.

Authors:  Elizabeth O Stenger; Brian R Rosborough; Lisa R Mathews; Huihui Ma; Markus Y Mapara; Angus W Thomson; Hēth R Turnquist
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.